Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May
16
2016
Adaptive NK Cell Therapy Advancing Toward First-in-Human Clinical Trial in Collaboration with University of Minnesota Program to be Presented Today at Innate Killer Summit 2016 SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical... Read All »
May
09
2016
Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May ... Read All »
May
02
2016
SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Monday, May 9, 2016 at 5:00 p.m... Read All »
Apr
05
2016
SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overvie... Read All »
Mar
03
2016
ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunothera... Read All »
Feb
25
2016
SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, March 3, 2016 at 5... Read All »
Feb
21
2016
Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 SAN DIEGO, Feb. 21, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ... Read All »
Feb
03
2016
SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview... Read All »
Jan
26
2016
SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today the U.S. Food and Drug Administration (FDA) has cleared the Company's investigational new drug (IN... Read All »
Jan
06
2016
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a c... Read All »
Dec
07
2015
Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Prevention of Acute Graft-versus-H... Read All »
Dec
03
2015
SAN DIEGO, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting at the Oppenheimer & Co.... Read All »
Nov
05
2015
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that it will present its strategy for developing off-the-shelf cancer immunotherapeutics using its nov... Read All »
Nov
05
2015
First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical comp... Read All »
Nov
03
2015
Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual MeetingFirst-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN DIEGO, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therap... Read All »
= add release to Briefcase